News
Enrollment is now ongoing in a first-in-human clinical trial testing EPI-321, an epigenetic therapy designed to address FSHD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback